Stockwinners Market Radar for October 22, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:50 EDT Cathie Wood's ARK Investment bought 47.8K shares of Crispr Therapeutics today

20:49 EDT Cathie Wood's ARK Investment bought 170.6K shares of Tempus AI today

18:49 EDT Prologis CEO: Things are very good, our future is bright - In an interview on CNBC's Mad Money, Hamid Moghadam said he's running the company for the long term and doesn't worry about quarterly results. He expects demand to normalize after the Presidential election. He's seeing "insatiable demand" for data centers due to the growth of AI. The company has been in data centers since 1999 and it's well-positioned to take advantage of the increase in demand, he noted.

18:00 EDT Berry Global and Glatfelter announce record date for spin-off - Berry Global Group (BERY) and Glatfelter (GLT) announced that Berry has set a record date of the close of business on November 1 for the proposed spin-off of its Health, Hygiene and Specialties Global Nonwovens and Films business. The spin-off and merger of Berry's HHNF Business with Glatfelter are expected to be completed on November 4, subject to the satisfaction or waiver of the closing conditions for the transaction. Subject to the satisfaction or waiver of the closing conditions, on November 4 Berry will distribute all of the shares of stock of its wholly owned subsidiary that owns the HHNF Business to Berry stockholders as of the close of business on the November 1 record date by means of a pro rata distribution, Spinco will merge into a subsidiary of Magnera, and the shares of Spinco distributed to Berry stockholders will convert into the right to receive Magnera shares, as illustrated in the hypothetical below. Upon completion of the merger, Berry stockholders are expected to collectively own approximately 90% of the outstanding shares of Magnera common stock on a fully-diluted basis, and current Glatfelter shareholders are expected to collectively own approximately 10% of the outstanding shares of Magnera common stock on a fully-diluted basis. The spin-off and merger remain subject to the satisfaction or waiver of certain conditions including, but not limited to, approval by Glatfelter shareholders of certain matters related to the transactions. If the closing conditions are not satisfied or waived in advance of November 1 Berry may elect to change the record date to a later date.

17:37 EDT Seagate says it sees potential for significant revenue growth in in FY25 - Says seeing increasingly favorable business landscape. Says sees potential for significant revenue growth in in FY25. Says well-positioned to support further demand growth. Says seeing healthy industry supply dynamics. Says wants HAMR to be accretive to gross margin. Says confident that can happen in the near term. Comments taken from Q1 earnings conference call.

17:33 EDT Sirius XM raises Q3 dividend 1.5% to 27c per share - The quarterly dividend is payable in cash on November 21, 2024.

17:17 EDT Okta Chairman Todd McKinnon sells $17M in company shares - Okta Chairman Todd McKinnon disclosed the sale of 224,533 shares of company stock at $74.62 per share on October 18, for a total transaction amount of $16,755,55.

17:07 EDT ESPN says WNBA Finals game 5 most viewed WNBA Finals game in 25 years - Disney's ESPN said that Sunday night's Game Five matchup of the WNBA Finals between the Minnesota Lynx and eventual champion New York Liberty was the most-viewed WNBA Finals game in 25 years across all networks, according to Nielsen. The audience for the game peaked at 3.3M viewers in Game Five, and the 2024 WNBA Finals across five games were up 115% compared to the 2023 WNBA Finals. Reference Link

17:05 EDT Baker Hughes reports Q3 adjusted EBITDA $1.21B, up 23% y/y

17:03 EDT Douglas Elliman appoints Michael Liebowitz as CEO - Douglas Elliman (DOUG) announced that Howard M. Lorber has decided to retire from his position as President, CEO and Chairman of the Board. Douglas Elliman Board Director Michael Liebowitz has been appointed Chairman and CEO of Douglas Elliman. Liebowitz is an entrepreneur, private investor, and seasoned business executive with extensive experience founding, acquiring, and monetizing businesses in the insurance and financial industries. In the past 25 years, Liebowitz has acquired or been a founder of companies, including Harbor Group Consulting, National Financial Partners (NFP), Innova Risk Management, and High Street Valuations. He currently serves as Chairman and CEO of Nocopi Technologies.

16:58 EDT Enphase Energy down 9% at $84.10 after miss on Q3 earnings, Q4 outlook - Shares of Enphase Energy are down 9% or $8.13 at a 52-week low of $84.10 afterhours following the company's Q3 results and Q4 revenue guidance missed consensus estimates. Enphase results are also weighing on other Solar energy stocks: SolarEdge Technologies (SEDG) is down 4% at $16.90, First Solar (FSLR) is down 1.1% at $199.25, and Sunrun (RUN) is down 2.2% at $13.73 afterhours.

16:51 EDT Wheels Up signs commitment letter with Bank of America for $332M credit facility - Wheels Up (UP) has entered into a commitment letter with Bank of America (BAC) for a new, five-year, up to $332M senior secured revolving credit facility. The company anticipates that the revolving facility will close concurrently with the closing of the GrandView acquisition in the Q4. Wheels Up expects to utilize the revolving facility to fund several actions, including the GrandView acquisition; the redemption of all outstanding equipment notes on the company's owned aircraft; and general corporate purposes. The financing is also expected to deliver up to $115M of additional cash to the balance sheet of Wheels Up and provides future revolving borrowing availability under certain conditions, with which Wheels Up expects to opportunistically acquire additional Phenom and Challenger aircraft in the future as it completes its fleet modernization plan. Delta Air Lines is expected to provide credit support for the new financing, enhancing Wheels Up's access to capital and on more attractive terms than would otherwise be available.

16:49 EDT Ocean Biomedical receives noncompliance letter from Nasdaq - Ocean Biomedical announced that it received a letter from Nasdaq stating that on April 18, May 22 and August 19, staff notified the company that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) because it had not filed its Form 10-K for the year ended December 31, and its Forms 10-Q for the periods ended March 31 and June 30, respectively. Based on its review and the materials submitted on June 17 and August 27, staff granted the company an exception until October 14 to regain compliance with the rule. Upon further review, staff determined that the company did not meet the terms of the exception. Specifically, the company has not filed the either its Form 10-K or Forms 10-Q as required by the rule. The company will appeal staff's determination to a hearings panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

16:48 EDT DBV Technologies jumps 80% to $1.26 after Viaskin regulatory update

16:47 EDT PetIQ stockholders vote to approve merger agreement to be acquired by Bansk - PetIQ announced that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ's common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5B. Upon completion of the proposed transaction, PetIQ's common stock will no longer be listed on the Nasdaq, and PetIQ will be privately held and continue to be operated independently by the company's executive team.

16:46 EDT Pfizer announces FDA approval of Abrysvo - Pfizer announced that the U.S. FDA has approved Abrysvo, the company's bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Abrysvo now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.

16:42 EDT Packaging Corp. up 2% afterhours at $222 after Q3 earnings beat

16:40 EDT Manhattan Associates down 7% afterhours at $272 after Q3 results

16:35 EDT Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint - The company also announces it "expects its current cash position to fund planned operations into 2027 and through multiple upcoming clinical readouts, including two additional readouts in MDD with ALTO-203 and ALTO-300 expected in the first half of 2025." Shares are down 47% or $6.78 afterhours at $7.75.

16:33 EDT Alto Neuroscience's Phase 2b study of ALTO-100 did not meet primary endpoint - Alto Neuroscience "announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Asberg Depression Rating Scale, compared to placebo. The favorable safety and tolerability profile of ALTO-100 was consistent with previously reported studies. The randomized, double-blind, placebo-controlled Phase 2b study was designed to evaluate ALTO-100 in adults with MDD, defined by an objective, memory based cognitive biomarker assessed prior to randomization. The primary endpoint was the change from baseline to the end of the 6-week double-blind treatment period on the MADRS, which is the standard regulatory endpoint in depression. The study was conducted across 34 sites in the U.S. and enrolled 301 adults with MDD. The biomarker-defined MDD patient group treated with ALTO-100 did not demonstrate a statistically significant improvement in depressive symptoms compared to placebo. ALTO-100 did not demonstrate benefit over placebo on the pre-specified key secondary analyses. ALTO-100 continued to demonstrate a favorable safety and tolerability profile, with no new safety signals observed in this study as compared to the previously completed clinical trials of ALTO-100. The most common adverse events from the trial related to treatment with ALTO-100 were headache, nausea, and abnormal dreams - all of which were experienced at similar rates to placebo. The Company expects to complete analysis of the full data set to determine the most appropriate next steps, if any, to further evaluate ALTO-100 in MDD."

16:31 EDT Avery Dennison expands RFID adoption in grocery retail industry - Avery Dennison (AVY) "announced it will begin working with The Kroger Co. (KR) to build a better associate and customer experience through RFID inventory automation technology. This collaboration makes item-level digital identification possible, enabling more frequent and more accurate inventory information to maximize freshness, reduce waste and improve the associate experience. This strategic collaboration will begin in the bakery department, implementing RFID-embedded labels on each item, providing significant time savings and valuable data to automate inventory management and freshness optimization. It is a foundational step in delivering a more seamless customer and associate experience across all fresh categories long term."

16:23 EDT McDonald's sinks 9% to $285 after CDC says burgers linked to E.coli

16:22 EDT Dominion closes transaction to sell 50% interest in CVOW to Stonepeak - Dominion Energy announced that it has closed on a transaction to sell a 50% noncontrolling interest in the Coastal Virginia Offshore Wind, or CVOW, commercial project to Stonepeak. Dominion Energy will retain full operational control of the construction and operations of the project, and Stonepeak will have customary minority rights. With this transaction, Dominion Energy has now successfully completed its business review debt reduction initiatives. During the review, the company announced transactions that represent approximately $21B of debt reduction. With the closings of the Cove Point LNG, East Ohio Gas, Questar Gas and Wexpro, and Public Service Company of North Carolina sales; and completion of the fuel securitization at Dominion Energy Virginia and the offshore wind partnership, Dominion Energy has now achieved 100% of the business review target. The 2.6-gigawatt CVOW, the largest offshore wind farm currently under construction in the United States, is on schedule to generate enough clean, renewable energy to power up to 660,000 homes once fully constructed in late 2026. CVOW will consist of 176 turbines and three offshore substations in a nearly 113,000-acre lease area off the coast of Virginia Beach. At closing, Dominion Energy received proceeds of $2.6B, representing reimbursement of approximately 50% of project-to-date capital investment. Stonepeak will fund 50% of remaining project costs as they are incurred, subject to certain conditions as previously disclosed.

16:21 EDT Matador raises fixed quarterly dividend 25% to 25c per quarter - Matador said its Board of Directors increased its fixed quarterly dividend by 25% to $0.25 per quarter, or $1.00 per share on an annual basis, from the prior dividend of $0.20 per quarter. This was the fifth dividend increase in four years and is further evidence of the confidence of the Board and our senior staff in Matador's future. Since 2021, Matador has doubled the value of its assets and returned $230 million in dividends to its shareholders.

16:20 EDT Starbucks falls 4% to $92.75 after preliminary results miss estimates

16:19 EDT Matador sees Q4 average daily oil equivalent production 171,480 Boe/d - Matador anticipates its average daily oil equivalent production of 171,480 BOE per day in the third quarter of 2024 to grow by 15% to a midpoint of approximately 198,000 BOE per day in the fourth quarter of 2024. This production growth is a result of the production associated with the Ameredev acquisition as well as continued strong results from Matador's existing assets. Matador is currently operating nine drilling rigs in the Delaware Basin and expects to operate nine drilling rigs for the remainder of 2024. Matador elected to accelerate the completion of 11 additional wells on the newly acquired Ameredev properties and expects 4.0 additional net operated wells to be turned to sales in 2024 on other properties. Due to this accelerated timing difference, Matador increased its full-year 2024 capital expenditure guidance range by $50 million. At October 22, 2024, Matador expects D/C/E capital expenditures for the fourth quarter of 2024 will be approximately $205 to $305 million, which is still a 23% decrease as compared to $329.9 million for the third quarter of 2024. Matador estimates its proportionate share of midstream capital expenditures (over 90% allocated to Pronto) to be approximately $42 to $62 million in the fourth quarter of 2024, which is a 6% increase as compared to $48.9 million in the third quarter of 2024 due to the construction schedule of Pronto's new processing plant, which is on time and on budget.

16:18 EDT Gyre: Last patient completes trial evaluating F351 for CHB-liver fibrosis - Gyre Therapeutics announced that the last patient in Gyre Pharmaceuticals' pivotal Phase 3 trial in the People's Republic of China or PRC evaluating F351 hydronidone for Chronic Hepatitis B CHB -associated liver fibrosis has completed the 52-week study. Gyre Pharmaceuticals expects to report topline data from this trial by the first quarter of 2025. "The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our development pipeline. We are grateful to the patients, researchers, trial investigators, and various teams who supported this trial and look forward to sharing data in the first quarter of 2025," said Han Ying, Ph.D., CEO of Gyre Therapeutics. "Furthermore, we are excited to potentially use these results to spur initiation of our Phase 2 clinical trial in the United States evaluating F351 for Metabolic Dysfunction-Associated Steatohepatitis MASH -associated fibrosis in 2025."...China's National Medical Products Administration NMPA designated F351 as a "Breakthrough Therapy" in 2021.

16:17 EDT Mustang Bio treatment of malignant glioma granted FDA orphan status - Mustang Bio was granted orphan designation from the FDA for a treatment of malignant glioma, according to a post to the agency's website. Reference Link

16:13 EDT Starbucks reports FY24 SSS down 2% - The company states: "For the full fiscal year 2024, global comparable store sales declined 2%, and consolidated net revenues increased 1% to $36.2 billion, also a 1% increase on a constant currency basis. GAAP earnings per share is $3.31, down 8% over prior year. Non-GAAP earnings per share is also $3.31, declining 6% on a constant currency basis. The lower-than-expected performance for the full fiscal year was a result of pronounced traffic decline, including a cautious consumer environment, and our targeted and accelerated investments not improving customer behaviors, as well as the macro and competitive environment in China pressuring our results further."

16:11 EDT Starbucks reports Q4 SSS down 7% - The company states: "The company's results were primarily driven by softness in North America's revenues in the quarter, specifically a 6% decline in U.S. comparable store sales, driven by a 10% decline in comparable transactions, partially offset by a 4% increase in average ticket. The accelerated investments in an expanded range of product offerings coupled with more frequent in-app promotions and integrated marketing to entice frequency across the customer base did not improve customer behaviors, specifically traffic across both Starbucks Rewards and non-SR customer segments, resulting in lower-than-expected performance. Additionally, China comparable store sales declined 14%, driven by an 8% decline in average ticket compounded by a 6% decline in comparable transactions, weighed down by intensified competition and a soft macro environment that impacted consumer spending."

16:07 EDT Seagate raises quarterly dividend to 72c per share from 70c - The dividend is payable on January 6, 2025 to shareholders of record as of the close of business on December 15, 2024.

16:06 EDT Rollins raises quarterly dividend 10% to 16.5c per share - Rollins announced that the Board of Directors declared a regular quarterly cash dividend on its common stock of 16.5c per share payable December 10 to shareholders of record at the close of business on November 12. This represents an increase of 10% from the same quarter a year ago.

16:03 EDT Texas Instruments CEO: Industrial continued to decline sequentially - Regarding the company's performance and returns to shareholders, Haviv Ilan, TI's president and CEO, made the following comments: "Revenue decreased 8% from the same quarter a year ago and increased 9% sequentially. Industrial continued to decline sequentially, while all other end markets grew. Our cash flow from operations of $6.2 billion for the trailing 12 months again underscored the strength of our business model, the quality of our product portfolio and the benefit of 300mm production. Free cash flow for the same period was $1.5 billion. Over the past 12 months we invested $3.7 billion in R&D and SG&A, invested $4.8 billion in capital expenditures and returned $5.2 billion to owners. TI's fourth quarter outlook is for revenue in the range of $3.70 billion to $4.00 billion and earnings per share between $1.07 and $1.29. We continue to expect our fourth quarter effective tax rate to be about 13%."

15:49 EDT California AG announces $7.5M settlement with Walmart - California Attorney General Rob Bonta announced a settlement with Walmart, resolving allegations that the retail corporation unlawfully disposed hazardous waste and medical waste from their facilities statewide to municipal landfills. As part of the settlement, Walmart will be required to pay $7.5M in penalties and costs and comply with injunctive terms. Attorney General Bonta is joined by the California Department of Toxic Substances Control and the district attorneys of Alameda, Fresno, Monterey, Orange, Riverside, Sacramento, San Bernardino, San Diego, San Joaquin, Solano, Tulare, and Yolo Counties, the AG stated. Reference Link

15:21 EDT BioSig Technologies to resume trading on Nasdaq following successful appeal - BioSig Technologies announced its successful appeal to the Nasdaq Panel, and as a result the company's common stock will resume trading on the Nasdaq at the open of trading on Wednesday, October 23. The company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities, or MVLS, requirement previously became non-compliant. BioSig's CEO, Anthony Amato stated, "We'd like to thank Nasdaq and its leadership for their diligence and attention to detail working through the complexity of our case. We additionally would like to extend our gratitude and appreciation to our attorneys and advisors who provided us with excellent guidance during this appeal. Lastly, I would like to thank our many shareholders for their continued support during this extremely challenging year. This is a very positive development for our company, as we are determined to restore shareholder value."

14:41 EDT Dye & Durham confirms it expanded review scope to consider a possible sale - Dye & Durham Limited, at the request of CIRO, responded to a media report that it is exploring a sale after receiving takeover interest. The company confirms that it has expanded the scope of its previously commenced strategic review process to consider additional opportunities to enhance shareholder value that may include, but are not limited to, a sale of the company, merger, divestiture of assets, or other strategic transactions. There can be no assurance that the strategic review process will result in any transaction or other alternative, nor any assurance as to its outcome or timing. There is no timetable for completion of this process and Dye & Durham does not intend to comment further unless and until it determines that further disclosure is necessary or appropriate.

14:16 EDT Nexalin announced planned clinical trial utilizing Gen-3 Halo headset - Nexalin Technology announced plans to commence a new clinical trial in collaboration with the University of California, San Diego. Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation with the San Diego VA to recruit some of the patients for the study who have been victims of Traumatic Brain Injury. This trial will focus on the effectiveness of Nexalin's next-generation Gen-3 Halo headset, designed to be used in a virtual clinic model, allowing patients to receive treatment from the convenience and privacy of their own home thus overriding the inconvenience and stigma of visiting a psychiatry office or VA Hospital. This breakthrough approach aims to expand access to care for veterans suffering from mild Traumatic Brain Injury without the need for frequent hospital or clinic visits. The Gen-3 Halo headset incorporates Nexalin's proprietary Deep Intracranial Frequency Stimulationtechnology, utilizing an advanced 15 milliamp waveform. Building on the success of a previous trial using the Gen-2 15 mAmp console device, the Gen-3 model offers enhanced convenience for in-home treatment while maintaining clinical precision. The new trial will seek to replicate the earlier results, which showed significant improvements in MEG signals and reductions in pain symptoms for mTBI patients. The study titled, "MEG Study of the Transcranial Electrical Stimulation Treatment for Mild Traumatic Brain Injury using the Nexalin Halo Headset that Utilizes the Advanced 15 Milliamp Waveform," will evaluate the effects of Nexalin's Gen-3 Halo headset on brain activity and symptom relief in veterans, all while leveraging the ease and accessibility of virtual treatment. Nexalin's program is aligned with the Veterans Administration's stated objective of expanding therapeutic telehealth services and expertise for veterans suffering with mTBI, as indicated in their 2025 Professional Judgement Budget. This budget also included over $17B allocated towards veterans' mental health services, which represents a significant area of interest for the VA.

13:49 EDT Steel Dynamics' VP Anderson sells $1.3M in company shares - Steel Dynamics' VP James Anderson disclosed the sale of 10,000 shares of company stock at $129.55 per share on October 22, for a total transaction amount of $1,295,450.

13:06 EDT FAA issues final rule for pilot training, qualifications for powered lifts - The Federal Aviation Administration, or FAA, said it is "ready for powered lift, which will be the first completely new category of civil aircraft since helicopters were introduced in the 1940s. Powered lift operations include air taxis, cargo delivery and a variety of operations within urban and rural areas." The agency has issued a final rule for the qualifications and training that instructors and pilots must have to fly aircraft in this "powered-lift" category, which have characteristics of both airplanes and helicopters. The rule also addresses their operational requirements, including minimum safe altitudes and required visibility. The rule is the final piece in the puzzle for safely introducing these aircraft in the near term. The rule makes changes to numerous existing regulations and establishes a Special Federal Aviation Regulation with new requirements to facilitate instructor and pilot certification and training; applies helicopter operating requirements to some phases of flight and adopts a performance-based approach to certain operating rules; allows pilots to train in powered-lift with a single set of flight controls; legacy rules require two flight controls - one for the student and one for the instructor. Publicly traded companies in the space include Joby Aviation (JOBY) and Archer Aviation (ACHR).

12:18 EDT Spotify, Trade Desk move higher after Axios report of ad exchange

12:09 EDT HSBC simplifies organizational structure into four businesses - In an earlier regulatory filing, HSBC Holdings announced that it is simplifying its organisational structure into four businesses to accelerate delivery against its strategic priorities. From 1 January 2025, the Company will operate through four businesses with clear lines of responsibility: Hong Kong; UK; Corporate and Institutional Banking; International Wealth and Premier Banking. The company said, "The changes will reduce the duplication of processes and decision making that are built into the current structure and will result in greater alignment and agility in serving our customers. The Group's functions will be realigned to support the four new businesses. Being the market leader in our home market of Hong Kong is one of our clear strengths as a business and remains a top strategic priority. The new "Hong Kong Business" will comprise "Personal Banking" and "Commercial Banking" under the business oversight of David Liao and Surendra Rosha at the Group Operating Committee, for both HSBC as well as Hang Seng Bank. Our UK ring-fenced bank has a leading market position in our home market of the UK and will continue to be a critical pillar of our strategy. The new "UK Business" will comprise UK "Personal Banking" and UK "Commercial Banking," including Innovation Banking under the sole business oversight of Ian Stuart. We are a market leader in global wholesale banking, especially in cross-border Transaction Banking, and in Capital Markets, underpinned by a strong balance sheet with an enviable deposit franchise. HSBC's global network remains a key differentiator of our business, with our presence in more than 50 markets. We are creating a new Corporate and Institutional Banking business through the integration of our Commercial Banking business with our Global Banking and Markets business and with the geographic region of the Western Markets, which is a predominantly wholesale banking region. Michael Roberts will lead Corporate and Institutional Banking and Western Markets. One of our greatest strategic growth opportunities is in international wealth - particularly in Asia and the Middle East, capitalising on our established brand and heritage. Our new International Wealth and Premier Banking business will bring together our Premier banking focussed businesses outside of Hong Kong and the UK, our Global Private Bank, and our wealth manufacturing businesses, Asset Management and Insurance. Barry O'Byrne will lead International Wealth and Premier Banking. As part of our new Group organisational structure, we are simplifying our geographic set up. The "Eastern Markets" will bring together the Asia-Pacific region and the Middle East region and will be overseen by David Liao and Surendra Rosha. The "Western Markets" will comprise the non-ring-fenced bank in the UK, our Continental European business and the Americas and will be overseen by Michael Roberts. In line with the more simplified structure, the Group Executive Committee of 18 members will be replaced by a new Group Operating Committee comprised of 12 members. The Group OpCo will serve as the leading decision-making executive committee of the firm. These changes will be effective from 1 January 2025."

12:01 EDT Herc Holdings rises 13.7% - Herc Holdings is up 13.7%, or $23.08 to $192.15.

12:01 EDT Mueller Industries rises 14.1% - Mueller Industries is up 14.1%, or $10.13 to $82.21.

12:00 EDT Sunlands Online falls -16.1% - Sunlands Online is down -16.1%, or -$1.23 to $6.45.

11:58 EDT Banzai regains compliance with Nasdaq minimum bid price rule - Banzai International announced that it has received notice from The Nasdaq Stock Market LLC informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rules for continued listing. To regain compliance with the Rule, the company's Class A common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days; on October 18, Nasdaq informed the company it achieved compliance with such Rule.

11:48 EDT Trump Media staff complains to board about management practices, NYT reports - Trump Media & Technology Group has soared on the stock market over the past month amid rising turmoil internally, the New York Times' Matthew Goldstein reports, citing people with knowledge of the matter. The company has dismissed or pushed out at least three senior managers in recent weeks after several workers anonymously sent a letter to the board accusing CEO Devin Nunes of mismanagement. In the letter, staff said Nunes' "directive" to hire foreign contractors was inconsistent with "the 'America First' principles we stand for" and noted Nunes has not formally addressed staff in two years, adding "this lack of transparency has left employees in the dark about the company's vision, strategy and future." Reference Link

11:46 EDT McCormick sees long-term EPS growth 9%-11%, net sales growth 4%-6% - Sees long-term operating income growth 7%-9%.

11:42 EDT McCormick: Acquisitions a 'core strength' of long-term growth objectives

11:26 EDT Reitar Logtech Holdings Ltd trading resumes

11:22 EDT Lockheed Martin: Baseline sales through 2027 reflects low single digit growth - Sees 10-20bps improvement in segment margins per year. Sees low single digit growth CAGR in free cash flow through 2027.

11:15 EDT Germany finds mpox infection in country contracted abroad - Germany's disease control agency, the Robert Koch Institute, announced that an mpox infection that was contracted abroad had been detected within the country. "The RKI does not currently assume an increased risk from clade I viruses in Germany, but is monitoring the situation very closely and will adapt its recommendations if necessary," the institute added. Reference Link

11:11 EDT Altair Engineering up 8% after Reuters says company considering sale - Shares of Altair Engineering are up $7.36, or 8%, to $102.54 following Reuters' report about the company receiving acquisition interest.

10:32 EDT First Horizon General Counsel Charles Tuggle to retire in 2025 - First Horizon Corporation announced the appointment of Lang Wiseman as Deputy General Counsel, effective November 1, 2024. Wiseman will transition into the General Counsel position on January 1, 2025, succeeding Charles Tuggle, who will retire in 2025 after 16 years of service. Wiseman comes to First Horizon from the law firm Baker Donelson Bearman Caldwell & Berkowitz, P.C., where he represented a diverse portfolio of clients across various sectors.

10:27 EDT Freeport-McMoRan says will continue to be disciplined in deploying capital - Reiterates financial policy priorities. Says global team is focused on driving value, committed to executing on operational plans.

10:24 EDT Freeport-McMoRan reaffirms goal of 800M lbs/annum from leaching initiative - Says continuing to build momentum with leaching initiative. Says goal is achieve 800M lbs/annum from this initiative. Says advancing investments in automation, tailings infrastructure, housing at Bagdad. Says targeting investment decision in 2025 for Bagdad expansion. Says targeting incremental addition of 300M-400M lbs./year beginning in 2030s at Lone Star. Says targeting EIS submission for El Abra by year-end 2025. Says making progress on Kucing Liar project in Indonesia

10:11 EDT Freeport-McMoRan: 'Well-positioned' to benefit from fundamental copper outlook - Says team continues to deliver on operating plans. Says generated strong margins, cashflows during the quarter. Says leach technologies are delivering results. Says optimistic about markets company serves. Says continues to see secular demand trends associated with electrification. Says demand for China continues to be supported by investments in electrical grid. Comments taken from Q3 earnings conference call.

10:02 EDT BAE Systems announces strategic partnership with Aerospike - BAE Systems announced a strategic partnership with Aerospike to develop future data-driven capabilities for the U.S. Army and other Department of Defense programs. Aerospike joins BAE Systems' Mission Advantage technology partnership program. "Aerospike is foundational to our data-centric solutions for the U.S. Army and DoD, as our customers push towards managing massive amounts of disparate data while leveraging advanced AI tools," said Daniel Perkins, director of Strategy & Technology Partnerships for BAE Systems' Intelligence & Security sector.

10:00 EDT General Motors rises 7.4% - General Motors is up 7.4%, or $3.60 to $52.53.

10:00 EDT Oklo falls -11.7% - Oklo is down -11.7%, or -$2.62 to $19.69.

10:00 EDT Genuine Parts falls -17.4% - Genuine Parts is down -17.4%, or -$24.95 to $118.17.

09:51 EDT Unisys settles SEC investigation into cybersecurity incidents for $4M - Unisys said it has reached a non-scienter-based administrative proceeding settlement, on a neither admit nor deny basis, with the Securities and Exchange Commission in connection with the SEC investigation the company previously disclosed. The violations relate to the company's policies, procedures, and risk disclosures related to certain cybersecurity incidents, and cybersecurity incident escalation matters that the Company disclosed in November 2022. This settlement fully resolves the company's SEC investigation. Unisys "concluded that it is in the best interests of the Company and its stockholders to constructively resolve this matter with the SEC." Under the terms of the settlement, the company consented to the entry of an order asserting violations of non-scienter-based provisions of the federal securities laws and rules promulgated thereunder and a cease and desist from committing or causing violations of those securities laws. The company agreed to pay within ten days of the entry of the order a $4M civil penalty, which was fully accrued in the company's 2023 financials.

09:48 EDT Genuine Parts falls -17.7% - Genuine Parts is down -17.7%, or -$25.29 to $117.83.

09:48 EDT Endeavour Silver rises 4.8% - Endeavour Silver is up 4.8%, or 24c to $5.39.

09:47 EDT Mueller Industries rises 9.2% - Mueller Industries is up 9.2%, or $6.63 to $78.71.

09:33 EDT Peloton announces partnership to sell Bike+ in 300 Costco stores - Peloton Interactive (PTON) and Costco (COST) announced a partnership where Costco will sell the Peloton Bike+ in 300 of its U.S. stores and on Costco.com this holiday season. Starting November 1, Costco members will be able to purchase an exclusive Bike+ bundle through February 15, 2025. "This partnership marks Peloton's first seasonal retail collaboration in the United States, partnering with a company dedicated to bringing its 136 million loyal members the best possible value on quality, brand-name merchandise," the companies said in a statement. The Peloton Bike+ will be self assembly, is expected to retail for $1,999 in-store and $2,199 online including delivery, and comes with a 48-month warranty.

09:31 EDT Nisun International partners with Beijing Tong Ren Tang in traditional medicine - Nisun International has signed a strategic cooperation agreement with Beijing Tong Ren Tang, marking its entrance into the traditional Chinese medicine, or TCM, supply chain. The partnership focuses on sourcing Cornus officinalis, or Chinese dogwood, an ingredient in TCM. Nisun plans to broaden its sourcing efforts to include other essential TCM ingredients. Nisun has also initiated share repurchases under its recently announced $15M buyback program.

09:24 EDT CEL-SCI announces potential impact on Multikine following FDA ODAC meeting - CEL-SCI announced the potential impact on the clinical development of its immunotherapy Multikine resulting from a recent FDA Oncologic Drugs Advisory Committee, or ODAC, meeting, a public forum. FDA advisory committees provide independent expert advice to the FDA on the safety and effectiveness of new and marketed drugs and help the agency make sound and informed decisions. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. The September 27 ODAC meeting evaluated the use of checkpoint inhibitors on patients with various cancers. PD-L1 is the biomarker most often used for patient selection for checkpoint inhibitors, the most successful class of cancer drugs including Keytruda and Opdivo. The FDA sought the ODAC's opinion on the following: adequacy of PD-L1 expression as a predictive biomarker for patient selection in this patient population; differing risk-benefit assessments in different subpopulations defined by PD-L1 expression; adequacy of the cumulative data to restrict the approvals of immune checkpoint inhibitors based on PD-L1 expression. Following a thorough analysis of peer-reviewed published data, the panel of experts on the ODAC voted 10-2 and 11-1 against the risk-benefit profile for PD-L1 inhibitors in various cancers in two separate votes. Most ODAC members expressed concerns about the lack of benefit demonstrated for patients with low PD-L1 expression, while some members pointed to evidence that the use of the immune checkpoint inhibitors may add unnecessary toxicities for patients while also increasing financial burdens on patients.

09:22 EDT Treasure Global enters service partnership with Octagram - Treasure Global announced the signing of a significant partnership agreement with Octagram Investment. This strategic collaboration aims to enhance user engagement and drive growth through the integration of innovative mini-game modules into the ZCity platform. This collaboration aims to drive growth and enhance user engagement through the integration of innovative technology modules into the ZCity platform, including interactive mini-games. As part of the agreement, OCTA will design and develop modules tailored to ZCity's growing user base, enhancing the platform's offerings by delivering engaging, interactive experiences. These developments are aligned with ZCity's strategy of evolving its digital ecosystem to provide seamless interaction between users and merchants across multiple services, including activities, travel, goods, and rewards. OCTA's role will extend beyond development phase to providing ongoing technical support, ensuring that the modules and mini-games remain fully integrated and functional as part of ZCity's evolving ecosystem. The games will comply with stringent data security, privacy regulations, and technical standards to offer a seamless experience across web and mobile platforms. The partnership, valued at $2.8 million, payable through the issuance of Treasure Global shares. This collaboration is expected to generate increased customer engagement on the ZCity platform and support TGL's continued growth in the competitive e-commerce market.

09:20 EDT Verizon updates broadbrand strategy with new fixed wireless subscriber goals - Verizon Communications announced an update to its broadband strategy, with new fixed wireless subscriber goals, household targets and broadband offerings to accelerate its premium broadband and mobility services to millions more customers nationwide. Verizon has more than 11.9 million total broadband connections as of the end of third-quarter 2024, up nearly 16 percent year over year. The update was given at a sell side analyst event following the release of the company's third-quarter 2024 results. Fixed Wireless subscribers on path to double by 2028: At the end of third-quarter 2024, the company had nearly 4.2 million fixed wireless subscribers, representing an increase of nearly 57 percent year over year. The company hit its previous goal of 4-5 million subscribers 15 months earlier than expected due to the demand from consumer and business customers as they continue to trust the reliability of the product and speed and ease of deployment. Verizon is expecting 8-9 million fixed wireless subscribers, doubling its current base, by 2028 and accelerating coverage to 90 million households in the same time period. Verizon will commercially launch its advanced mmWave solution for apartment and office buildings to address high population areas. The technology leverages existing infrastructure making it less expensive to build and faster to deploy. Continued deployment of C-band and mmWave will provide the performance and capacity needed to meet these goals and deliver the experience that customers expect from Verizon. Fiber network expected to grow to 35-40 million passings: Verizon will continue to look for opportunities to accelerate its ongoing Fios builds within the current footprint in nine states and Washington, D.C., giving more customers access to the industry-leading product. Verizon's recent agreement to acquire Frontier, the largest pure-play fiber internet provider in the U.S., is expected to expand Verizon's share of the nationwide broadband market, building upon Verizon's two decades of leadership at the forefront of fiber. Upon closing, Frontier is expected to bring in approximately 9-10 million fiber passings. In 2025 Verizon is targeting an expansion of Fios builds to up to 650,000 passings annually. Following the closing of the Frontier acquisition, Verizon expects the combined build to be up to 1 million or more passings annually. Verizon is expecting more than 30 million fiber passings in the combined Verizon/Frontier footprint by 2028. Over time, Verizon is expecting 35-40 million fiber passings. This will significantly expand Verizon's fiber footprint, accelerating the company's delivery of premium mobility and broadband services to current and new customers. Frontier's consumer fiber network can be immediately and seamlessly integrated upon closing directly into Verizon's award-winning Fios network, meeting existing Fios standards. Outlook and Guidance: Priorities remain unchanged: The company will maintain its capital allocation priorities, characterized by prudent investment in the business, a commitment to maintaining an industry-leading dividend, continued debt reduction, and efficient return of cash to shareholders, with buybacks to be considered when net unsecured debt to adjusted EBITDA ratio* is at 2.25x. For 2025, the company expects capital expenditures of $17.5-$18.5 billion, consistent with historical levels of capital intensity. Revised net unsecured debt to adjusted EBITDA ratio target of 2.0 to 2.25x.

09:14 EDT J.M. Smucker to divest Voortman cookie brand for $305M - J.M. Smucker has entered into a definitive agreement to sell its Voortman cookie brand to Second Nature Brands, a U.S.-based creator of premium snacks and treats controlled by CapVest Partners LLP. The all-cash transaction is valued at approximately $305M, subject to a working capital adjustment. The transaction includes all Voortman trademarks and the company's leased manufacturing facility in Burlington, Ontario, Canada. In addition, approximately 300 employees will transition with the business. The company also confirmed continued progress on the integration of Hostess Brands, and that it remains on track to achieve expected synergies of $100M from the acquisition by the end of FY26. The Voortman brand generated net sales of approximately $65M for the company's FY24, which represents a partial year of net sales reported in its Sweet Baked Snacks segment results following its acquisition on November 7, 2023. For FY25, the company anticipates full-year net sales from the Voortman brand to be approximately $150M. The company expects the divestiture to be dilutive to its adjusted EPS by approximately 25c on a full-year basis. The company anticipates using the net proceeds from the transaction to pay down debt, which will contribute an EPS benefit of approximately 10c on a full-year basis. The transaction is anticipated to close in Q3 of the company's current FY25.

09:11 EDT PacBio includes Onso platform in 10x Genomics Compatible Partner Program - PacBio (PACB) announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics (TXG) Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics' products and applications, thereby broadening the range of sequencing solutions available to researchers worldwide.

09:09 EDT Sportradar enhances partnership with NBA - Sportradar is enhancing its partnership with the NBA this season through the introduction of a suite of fan engagement solutions. These products represent the next phase in the evolution of basketball consumption benefitting not only the NBA but also operators and media partners. Sportradar, leveraging AI and its advanced, proprietary technology, has launched a suite of next-generation products for the NBA by accessing the full range of official NBA content, including skeletal tracking data.

09:08 EDT Know Labs names John Cronin interim CTO, Dominic Klyve chief science officer - Know Labs announced two additions to its executive leadership team. The new executives are John Cronin and Dominic Klyve. John Cronin joins the day-to-day team as interim CTO. Previously, Cronin was elected as a member of the company's board. Dominic Klyve, a long-time consultant and previous employee of the company, joins as chief science officer. Klyve previously served as lead data scientist at Know Labs.

09:07 EDT Neo-Concept completes acquisition of IP, R&D capabilities from affiliate - Neo-Concept International announced the completion of its acquisition of the intellectual property and research and development capabilities from its affiliate, Neo-Concept. This strategic acquisition empowers NCI with full ownership of the esteemed "Les100Ciels" and "SIU" brands, along with all related trademarks and trade names. Additionally, the transfer includes NCH's talented R&D teams, further enhancing NCI's potential for innovation.

09:07 EDT Intapp DealCloud selected by Alvarez & Marsal - Intapp announced that global consulting firm Alvarez & Marsal has selected Intapp DealCloud as its deal and pipeline management solution. Alvarez & Marsal's rapidly expanding Corporate Finance practice group will use DealCloud to manage origination, sales pipeline, and deal workflows.

09:06 EDT Anheuser-Busch invests additional $8M in flagship St. Louis Brewery - Anheuser-Busch announced a new $8M investment in its St. Louis brewery. Over the last 5 years, Anheuser-Busch has invested nearly $2B in its facilities across the country to help create and sustain jobs and drive economic prosperity in the communities where it operates and its employees call home.

09:06 EDT Starbox Group launches StarboxAI VI-Pro Live Streaming System - Starbox Group Holdings announced that its wholly owned subsidiary, Starbox Technologies is launching "StarboxAI VI-Pro - Live Streaming System," a platform designed to support Starbox's over 800 existing merchants in their live streaming social commerce efforts. This artificial intelligence-powered system enhances digital interaction and is expected to boost sales performance with automated content creation and real-time engagement tools. What distinguishes StarboxAI VI-Pro - Live Streaming System is its integration with the Company's existing cash rebates ecosystem, which currently serves Starbox's over 2 million existing users. The integration allows merchants to offer real-time cash rebates during live streaming events, creating a seamless experience for merchants and users alike, incentivizing users to engage and purchase products. Starbox Technologies will keep a percentage of the cash rebates generated from successful sales as revenue.

09:04 EDT Quad/Graphics to sell majority of European operations to Capmont for EUR41M - Quad/Graphics has entered into a definitive agreement to sell the majority of its European operations for EUR41M - approximately $45M - to Germany-based entrepreneurial private capital investment manager Capmont. Quad will maintain printing operations in locations that best support its MX offering. The transaction includes all employees and facilities for Quad/Graphics Europe print and ink-manufacturing headquartered in Wyszkow, Poland; the Peppermint agency in Warsaw, Poland; and Quad POS, which has locations throughout Europe. Excluded from the sale are Quad's shared services employees in Poland who support the company's integrated marketing platform in the Americas. The transaction is expected to close by year end 2024 pending customary regulatory clearances and other closing conditions. Quad expects to use the proceeds from the sale to reduce debt and make further investments in solutions that advance its MX offering. Quad established its European print operations in 1998 through a partnership with Winkowski and acquired Winkowski in 2008, later renaming it Quad/Graphics Europe. Quad purchased Marin's International SAS, a global leader in the point-of-sale display industry, in 2015, later renaming it Quad POS.

09:03 EDT Oncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534 - Oncternal Therapeutics announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer, mCRPC. Based on initial pharmacokinetic results, two additional dosing cohorts with twice daily, BID, oral dosing of ONCT-534 had been incorporated in the Phase 1/2 study ONCT-534-101. Overall, fifteen patients received ONCT-534 once daily in six dosing cohorts and six patients received ONCT-534 BID in two dosing cohorts. Based on a data cut off of September 30, 2024, the BID dosing schedule was well tolerated, with no related Grade 3 or higher toxicities. One patient, who experienced a rising PSA on ONCT-534 at 160 mg BID, had a subsequent 50% reduction in PSA after four weeks of ONCT-534 at 300 mg BID, and at the same time the CAT Scan showed a 16% reduction in target lesions compared to baseline. Enumeration and biomarker analysis of circulating tumor cells showed promising effects on expression of androgen receptor-regulated genes, and AR nuclear translocation in six additional patients. CTC analysis also showed that some patients who did not respond to ONCT-534 had prostate cancer that had developed neuroendocrine features, which are associated with AR independent disease.

09:02 EDT Neuraxis announces AMA established new CPT Category I Code for PENFS - NeurAxis announced that the American Medical Association, AMA, has established a new Current Procedural Terminology, CPT, Category I code for Percutaneous Electrical Nerve Field Stimulation, PENFS, procedures effective January 1, 2026.

09:00 EDT LPL Financial: William Fenwick joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor William "Bill" Fenwick of Fenwick Financial has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported serving approximately $210 million in advisory, brokerage and retirement plan assets, and joins LPL from First Kentucky Securities. Based in Louisville, Ky., Fenwick is a retired U.S. Marine Corps officer with 38 years of experience in the financial services industry. He believes his military experience, coupled with his astute study of the markets and economy, shaped his ability to guide clients through market fluctuations and build personal relationships that extend across generations.

08:57 EDT General Motors has seen 'a lot of inflation' on parts, labor on warranty claims - Says has found "some quality issues" in prior model years, but has fixed production lines. Expects to see labor cost inflation in 2025.

08:49 EDT General Motors sees 'similar performance' in 2025 vs. 2024 - Says cash flow "remains strong."

08:48 EDT ABVC BioPharma receives $50,000 in incremental licensing fees - ABVC BioPharma announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches. The payment, tied to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder and Attention Deficit Hyperactivity Disorder, is part of a broader agreement with AiBtl BioPharma. The MDD and ADHD pipeline, valued at $667M by third-party evaluators, continues to gain momentum as both companies advance their collaborative efforts towards discussion with big pharma for out-licensing and initiating the plan for the GAP-certified temperature-controlled farm.

08:44 EDT Safe Pro's Airborne Response enters agreement with Skydio - Safe Pro Group's Airborne Response division has entered into an agreement with Skydio, Inc. to offer hardware and software solutions for public safety, emergency services, disaster response, and critical infrastructure customers.

08:42 EDT SOBRsafe launches fully-integrated enterprise software solution - SOBRsafe announced the launch of its fully-integrated enterprise software solution for point-of-care screening and continuous monitoring. This new platform is expected to transform how health providers monitor and manage alcohol compliance, delivering unprecedented real-time visibility across multiple users and locations in one dynamic dashboard. The current methods for monitoring alcohol use are outdated and inefficient. They rely on invasive, unhygienic, physical testing and printed reports which can delay interventions and negatively impact patient care. SOBRsafe's transdermal alcohol detection devices, combined with the integrated enterprise software platform, offers a comprehensive solution. The advanced touch-based technology detects alcohol emitted through the skin, eliminating the need for breath, blood, or urine samples. Information is instantly reported and accessible via computer or mobile device, allowing providers to monitor hundreds of patients across various locations through a streamlined digital dashboard. This setup ensures immediate visibility into any detected alcohol use, enabling timely interventions and support. SOBRsafe's software offers real-time insights into alcohol use throughout the treatment journey, creating the first definitive electronic alcohol record across the continuum of care. The new software integrates device data into an intuitive desktop interface with user-friendly navigation, allowing health providers to aggregate all activities onto a single screen. This significantly enhances responsiveness and reduces recidivism, providing hope for improved patient outcomes. Moving beyond localized management, this software empowers providers to take holistic views of their organization. Moreover, the software features robust lookback capabilities that demonstrate historical performance and activity, a crucial ability for individuals needing to show compliance with third parties.

08:40 EDT Quantum BioPharma posts link to lawsuit against CIBC World Markets, RBC Dominion - Quantum BioPharma announces the Company, on 20th October 2024, had filed a complaint in the United States District Court for the Southern District of New York alleging that CIBC World Markets, RBC Dominion Securities, and others engaged in market manipulation schemes that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934. This lawsuit alleges that between 1st of January 2020, and 15th of August 2024 the Defendants and/or their customers used "spoofing" techniques to manipulate the share price of Quantum BioPharma shares. The Company is seeking damages of more than $700M. Due to a lot of inquiries the Company has posted a copy of the complaint on its website on the News page

08:38 EDT Turbo Energy teams with Connection to introduce SUNBOX home energy system - Turbo Energy announced that the Company has partnered with Florida-based Connection, the managing entity of brands operating in the performance marketing and lead generation sectors with focus on a broad range of industries, including the U.S. solar energy market. Pursuant to the strategic advisory agreement entered into on October 18, 2024, CH will employ its organization's market penetration capabilities and leverage its nationwide network of U.S. solar installation companies to assist Turbo Energy in introducing U.S. market share for the Company's proprietary, all-in-one, Artificial Intelligence-optimized SUNBOX solar energy storage system designed specifically for residential application.

08:38 EDT Mama's Creations engages UHY as independent auditor - Mama's Creations has engaged UHY as its independent auditor for the Company's fiscal year ending Jan 31, 2025. The change to the Company's independent registered public accounting firm was approved by the Audit Committee of its Board of Directors. UHY succeeds Rosenberg Rich Baker Berman, which was previously the independent auditor providing audit services to the Company. The change to the Company's independent auditor was made after careful consideration and was approved by the Audit Committee. The decision to change auditor was not as a result of any disagreement between the Company and RRBB on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures

08:36 EDT Autonomix announces 1-for-20 reverse stock split - Autonomix Medical announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect on October 24, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on October 25, 2024 on a post-split basis, under the existing ticker symbol "AMIX" but with a new CUSIP number 05330T 205.

08:36 EDT Celularity to submit 510(k) notification for Tendon Wrap in early 2025 - Celularity issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditing firm to complete the necessary financial reports. We filed our annual report on Form 10-K for fiscal year 2023 within the compliance period and our quarterly report on Form 10-Q for the first quarter 2024 on October 16, 2024. Additionally, we intend to file our Form 10-Q for the second quarter 2024 within the coming weeks. As stated in last week's announcement, the notice we received from Nasdaq has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols "CELU" and "CELUW," respectively...From time to time, we selectively assess opportunities to acquire existing products that we believe could complement and expand our commercial product portfolio. Last week, we announced the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience. We have sold in excess of $9 million of Rebound, which is reimbursed in POS 11, 12, and 32 via HCPCS Code Q4296 when medically necessary. As noted in that announcement, the acquisition of Rebound adds to our portfolio of placental-derived advanced biomaterial products, sales of which through the first half of 2024 were in excess of $24 million, which is greater than our full year sales in 2023. Looking to the future, we continue to advance product candidates for indications that include aging-associated and other degenerative diseases and disorders characterized by the progressive loss of function and/or structure of the affected tissues: Celularity Tendon Wrap, a high strength scaffold composed of collagen and other native proteins derived from decellularized human placental tissue that the Company is developing for use in the management and protection of tendon injuries. Celularity Bone Void Filler, an easy to handle, moldable bone void filler composed of collagen and other native proteins derived from decellularized human placental tissue that the Company is developing for use as a passive osteoconductive bone filler in the pelvis, extremities, and posterior-lateral spinal fusion settings as well as other skeletal defects. Celularity Placental Matrix, a fully resorbable device composed of extracellular matrix derived from decellularized human placental tissue that the Company is developing for use as a passive temporary wound covering and in aesthetics. We expect these human placental tissue-derived products to be regulated in the United States as a device under Section 510(k) of the Food, Drug and Cosmetic Act. Celularity Tendon Wrap, FUSE Bone Void Filler, and Celularity Placental Matrix each completed preliminary non-binding product classifications and jurisdictional assessments by the U.S. Food and Drug Administration Office of Combination Products to be regulated as a device by the FDA Center for Devices and Radiologic Health. Based on the OCP's preliminary assessment, we intend to submit a 510(k) notification for our Celularity Tendon Wrap in early 2025 and for our FUSE Bone Void Filler in the second half of 2025 and for Celularity Placental Matrix in 2026. We also are developing another product, Celularity Placental Dermal Filler Matrix, as a Class III medical device, for which we would be required to submit a premarket approval application to the FDA. We are working hard to execute our plan to expand Celularity's advanced biomaterial products business and continue to sharpen the focus of the mission-driven organization we have built over the past several months to ensure our team is lean, agile, and working to build shareholder value. With that said, we are confident in our previously stated guidance of expected combined Net Sales of our advanced biomaterial product and biobanking businesses to be in the range of $50 million to $56 million."

08:35 EDT Cadiz 's ATEC Water Systems wins $1.6M in three new sales contracts - Cadiz's operating subsidiary ATEC Water Systems was awarded three new sales contracts totaling $1.6M for arsenic, iron and manganese filtration systems. The systems will be delivered in 2025. ATEC will manufacture treatment systems in rural and suburban communities in California, Washington and Oregon that serve close to 100,000 people reliant on groundwater as their principal water supply. The filters will be capable of processing up to 10 million gallons per day. Cadiz continues to expect gross ATEC segment revenues to reach $15M for FY24 and anticipates strong segment growth in FY25. The ATEC treatment system uses patent-pending filter media processes to remove common groundwater contaminants by adsorption.

08:35 EDT HeartCore shifts CMS licensing contracts to drive longer sales contracts - HeartCore Enterprises announced a strategic shift from annual contracts to multi-year agreements around its core software business contracts. Since achieving profitability across its software business in Q1 2024, HeartCore has maintained a strong focus on its sales and marketing strategies to drive growth and sustain positive momentum. By September 2024, the Company tripled its new customer acquisition count while also reporting a fivefold increase in contract extensions from its existing customer base, both on a year-over-year basis. Building on this momentum, HeartCore has adopted a strategic shift to proposing multi-year agreements that provide customers with more comprehensive, long-term support while helping each client establish a robust CMS infrastructure.

08:34 EDT Sabre selected by World Travel as primary GDS partner - Sabre announced a new multi-year distribution agreement with World Travel, one of the top 10 largest Travel Management Companies in the U.S. The new agreement will allow World Travel agents to access the travel content available via Sabre's travel marketplace. The Sabre GDS aggregates, normalizes and distributes content from more than 400 airlines and hundreds of tour operators, rail, and car rental providers. World Travel will also adopt range of Sabre solutions, including the intelligent platform Sabre Red 360.

08:33 EDT TC Biopharm enters research pact with Dr. Carlos Maluquer de Motes - TC BioPharm announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox.

08:32 EDT Hesai named exclusive lidar provider for Leapmotor's vehicle platform - Hesai will be the exclusive provider of automotive long-range lidar for Leapmotor's next-generation vehicle platform. The platform's first model is expected to enter mass production in 2025. Hesai Technology will provide lidar products for multiple models of Leapmotor's next-generation new vehicle platform. The two companies have advanced intelligent driving projects for multiple new Leapmotor models. According to Leapmotor, as of September 23rd, it has already commenced sales in Europe, with over 200 dealers across 13 countries. The company plans to expand this footprint to 500 sales points in Europe by the end of 2025.

08:30 EDT Verisk, Guidewire launch Statistical Services accelerator integration - Verisk (VRSK) announced its latest advancement in statistical reporting technology with the launch of its Statistical Services accelerator integration with Guidewire (GWRE). This solution automates complex processes that extract highly granular policy and claims data, making it easier for insurers to satisfy statistical reporting and regulatory compliance requirements. This latest offering from Verisk's Core Lines Services is designed to directly help insurers effectively meet the industry's expanding data reporting requirements by driving operational efficiency and consistency.

08:28 EDT PodcastOne unveils tenth season of 'The Opportunist' podcast - PodcastOne announced the release of the latest season of its hit series, The Opportunist, hosted by veteran true crime author and podcast host Sara James McLaughlin. In this new season, Tim Ballard: Unmasking a Hero delves into the dramatic rise and fall of Tim Ballard, the embattled founder of Operation Underground Railroad. Known for his work rescuing trafficked children, Ballard's public persona hides darker allegations. In this season, McLaughlin takes listeners on a gripping investigative journey, featuring interviews with some of the women who have accused Ballard of sexual misconduct.

08:27 EDT Janover rebrands Groundbreaker platform as Janover Connect - Janover announced the rebranding of its real estate syndication software, Groundbreaker, to Janover Connect. This strategic move includes the launch of a new, state-of-the-art website designed to better communicate the platform's value proposition and align it more closely with Janover's suite of comprehensive commercial real estate solutions while showcasing Janover Engage, its new marketplace matching real estate syndicators and accredited investors. The new Janover Connect website offers an enhanced user experience, providing detailed insights into the platform's robust set of features. These include CRM, fundraising, investor portal management, investor reporting, investor communications, distribution automation, K-1 sharing, deal room tools and more. The website clearly showcases how Janover Connect enables syndicators to efficiently manage one or multiple real estate investments and handle all aspects of limited partner relations.

08:26 EDT DZS achieves U.S. BEAD Program manufacturing readiness certification - DZS announced that the company's U.S. manufactured electronic components have been certified as compliant with the domestic manufacturing requirement enumerated in the "Build America Buy America" waiver for the $42 billion Broadband Equity, Access, and Deployment Program. On October 16, 2024, the National Telecommunications and Information Association announced a list of specific equipment and suppliers self-certifying their compliance with the NTIA's final limited waiver of BABA requirements of the BEAD Program which included certain manufactured products such as Optical Line Terminals, OLT line cards, Optics pluggables and standalone Optical Network Terminals. DZS manufactures a wide range of OLTs and OLT line cards that are BABA certified, as well as a full portfolio of gateway ONTs with integrated WiFi and Layer 2 routing which makes them compliant with the BEAD wavier requirements.

08:22 EDT Envoy Medical announces AMA CPT Editorial Panel approved codes for AMEI - Envoy Medical announced that the American Medical Association, AMA, Current Procedural Terminology, CPT, Editorial Panel has approved five Category III CPT codes for totally implantable active middle ear implants, AMEI, a crucial development for the Company's already FDA-approved Esteem product. This marks the first time that there will be CPT codes for totally implantable active middle ear hearing implants like the Esteem device. With a new set of CPT codes, a path to reimbursement for the breakthrough Esteem Fully Implanted Active Middle Ear Implant, FI-AMEI, may begin to take shape.

08:20 EDT BOS Better Online Solutions receives $500,000 order from customer in India - BOS Better Online Solutions announced that its Supply Chain Division, which provides franchised distribution of electronic components, received a $500,000 order from a customer in India. The order is for delivery gradually by August 2025. Avidan Zelicovski, BOS' President, expressed confidence in the division's ability to expand its global sales, citing the success of achieving $6 million in overseas sales in 2023. Additionally, he highlighted that since the announcement on July 10, 2024, regarding initial sales to Greek customers, the division has received $280,000 orders from that territory.

08:19 EDT Quoin Pharmaceuticals announces further expansion of on-going NS studies - Quoin Pharmaceuticals announces the further expansion of its on-going Netherton Syndrome, NS, clinical studies to include two additional international sites in the United Kingdom, UK. These sites, Great Ormond Street Hospital and St. Thomas' Hospital, both in London, are recognized centers of excellence for treating Netherton Syndrome patients in the UK. Both sites have available cohorts of patients potentially eligible to participate in Quoin's studies. A Principal Investigator, PI, for the UK studies has been appointed and a Clinical Research Organization has been engaged. These clinical sites, as well as the previously announced site in Saudi Arabia, will operate under the auspices of Quoin's open Investigational New Drug application with the US Food and Drug Administration

08:19 EDT Radoff reiterates call for GSE Systems board Chair Gardner to make disclosures - Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, issued the below follow-up letter to the Chair of the Company's Board of Directors (the "Board"), Kathryn O'Connor Gardner, in response to the Company's filing of an amended merger agreement with Pelican Energy Partners ..Mr. Radoff previously announced his opposition to the Company's proposed take-private merger with Pelican and has repeatedly demanded the Board and Ms. Gardner release normal course forward-looking projections so shareholders can fairly evaluate the Pelican transaction.

08:17 EDT FuelCell, KHNP to pursue clean hydrogen production products in Korea - FuelCell Energy and Korea Hydro & Nuclear Power, KHNP, announced that the two companies have agreed to jointly pursue hydrogen energy business initiatives and have signed a memorandum of understanding, MOU, outlining the possibilities. The cooperative approach will focus on the development and implementation of advanced energy solutions using FuelCell Energy's solid oxide electrolysis hydrogen platform and KHNP's nuclear power plants within the scope of relevant laws and regulations. This initiative will combine South Korea's domestic clean energy sources with FuelCell Energy's electrolyzer platform that uniquely uses electricity and thermal energy sources to produce lower cost, domestic clean hydrogen, and diversify South Korea's hydrogen supply beyond imported fuels.

08:16 EDT Grifols partners with BARDA for PoC testing of ocular immunoglobulin - Grifols has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular surface immunoglobulin eye drops for their ability to treat ocular damage from sulfur mustard exposure. BARDA is part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. If the preclinical evaluation is successful, the United States Food and Drug Administration could eventually license what would be one of the first medical treatments to counteract the long-term effects of sulfur mustard ocular injury. Sulfur mustard, sometimes referred to as mustard gas, is a chemical warfare agent that reacts rapidly with ocular tissue and can cause pain, photophobia and mustard gas keratopathy, a corneal injury that can lead to blindness. Grifols will develop a treatment for sulfur mustard ocular exposure by repurposing an investigational OSIG therapeutic currently in development for dry eye disease. The nonclinical studies, conducted in partnership with BARDA, may provide evidence for the anti-inflammatory and immunomodulatory properties of OSIG and its ability to alleviate the long-term effects of sulfur mustard exposure. Specifically, research will investigate how OSIG's anti-inflammatory properties can prevent the immune system from mistakenly attacking self-antigens, which in this case are proteins modified due to exposure to sulfur mustard. In cases of sulfur mustard exposure, the immune system can errantly target these self-antigens. By neutralizing the immune response caused by the self-antigens, OSIG could help protect ocular tissue and support recovery in people exposed to sulfur mustard. Grifols announced in March 2023 a collaboration with Chicago-based Selagine, which focuses on developing novel therapeutics for ocular diseases, to treat DED with immunoglobulin eye drops. The potential treatment, expected to enter clinical development in the first half of 2025, would become the first immunoglobulin medicine indicated for DED, which affects more than 100 million people globally. Grifols' work with BARDA to create an OSIG to neutralize the effects of sulfur mustard ocular exposure comes shortly after the company's GigaGen subsidiary announced a contract with BARDA, worth up to $135 million over six years, to develop recombinant polyclonal antibody therapies for biothreats including botulinum neurotoxins.

08:15 EDT Chipotle introduces AI hiring platform - Chipotle is partnering with Paradox to introduce a new platform that aims to make hiring employees more efficient for its restaurant teams. Paradox's conversational hiring system will enable the General Managers in Chipotle's restaurants to spend less time on administrative tasks, including collecting basic information from candidates and scheduling interviews, and allow them to focus on their day-to-day operations. The technology, underpinned by Conversational AI, is expected to reduce the amount of time it takes to hire an employee for an in-restaurant position by as much as 75%. Paradox is currently being introduced in a phased approach across more than 3,500 restaurant locations, with plans for completion this month. The platform is multilingual and can converse with candidates in English, Spanish, French, and German.

08:14 EDT PDS Biotechnology presents rationale, design for study evaluating PDS01ADC - PDS Biotechnology announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate cancer will be discussed during an oral presentation at the 12th Annual Meeting of the International Cytokine & Interferon Society in Seoul, South Korea.

08:13 EDT Aligos announces FDA cleared IND for Phase 1 DDI study of ALG-000184 - Aligos Therapeutics announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, for a Phase 1 Drug-Drug Interaction, DDI, study of ALG-000184, a capsid assembly modulator, CAM-E, for the treatment of Chronic Hepatitis B, CHB. "The acceptance of our third U.S. IND is an important milestone for Aligos," said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "This IND clearance allows us to begin the next stages of our clinical development for ALG-000184, including the advancement of the compound into Phase 2 clinical trials. ALG-000184 is the first novel, oral drug candidate for the treatment of HBV infection that can inhibit multiple components of the viral lifecycle, leading to more complete suppression of the virus compared to other therapeutic modalities."

08:13 EDT Martin Midstream Partners shareholders Nut Tree and Caspian to oppose sale - Martin Midstream Partners, or MMLP, shareholders Nut Tree Capital and Caspian Capital intend to oppose the proposed sale of Martin Midstream Partners to Martin Resource Management, or MRMC, an affiliate of the company's general partner, for $4.02 per MMLP common unit not already owned by MRMC. Nut Tree and Caspian have combined economic exposure in the company of approximately 13.2% of the outstanding common units through certain cash-settled derivative agreements. Nut Tree and Caspian stated that they believe that "the proposed sale price significantly undervalues the company and its prospects, and that if the merger is completed on its current terms, MRMC will receive significant upside for itself that rightfully belongs to all MMLP unitholders". Nut Tree and Caspian intend to file a proxy statement with the SEC and solicit votes "against" the proposed transaction at the company's upcoming special meeting to be held to approve the related merger agreement. Both shareholder companies believe that the Conflicts Committee of the board did not fully explore potentially superior alternatives to the sale to MRMC.

08:11 EDT Veritone divests Veritone One media agency to Insignia Capital for $104M - Veritone announced that it has sold its media agency, Veritone One, to Insignia Capital. Total consideration from the divestiture is up to $104M, subject to customary purchase price adjustments and including up to $18M in cash subject to an earn-out based on Veritone One's achievement of certain net revenue targets during calendar year 2025. Net proceeds will be used to retire a significant portion of Veritone's term debt and to fund future operations. The transaction significantly strengthens Veritone's balance sheet and liquidity, allowing Veritone to concentrate on accelerating the growth of its enterprise AI software and solutions, powered by its proprietary aiWARE platform. This strategic focus is designed to enhance long-term shareholder value and position Veritone for sustained success in the AI sector. In addition to acquiring Veritone One, Insignia Capital Group simultaneously acquired Oxford Road, another leading audio advertising agency. The two entities will operate independently in the near-term but will leverage their combined scale, technology, analytics platform and industry expertise to deliver unparalleled performance for their clients.

08:10 EDT Taysha Gene Therapies to present biodistribution data from AAV9 analysis - Taysha Gene Therapies will present biodistribution data from an analysis of 28 non-human primates evaluating the delivery of AAV9 gene therapy vectors across five different studies using intrathecal delivery by lumbar puncture or intra-cisterna magna injection. The data will be presented during a poster presentation at the upcoming 31st Annual Congress of the European Society of Gene & Cell Therapy, taking place in Rome, Italy from October 22-25, 2024. These findings reinforce Taysha's clinical development approach utilizing IT administration to deliver AAV-based gene therapies designed to treat the genetic root cause of CNS diseases, including the TSHA-102 program in clinical evaluation for children, adolescents and adults living with Rett syndrome. "Findings from an analysis across five NHP studies showed that both IT and ICM administration led to comparable, consistent and widespread biodistribution of AAV9 vector throughout the brain and spinal cord regions," said Sukumar Nagendran, President and Head of Research & Development. "Importantly, these findings further support the clinical potential of IT administration as an effective, safe and minimally invasive delivery approach for broad targeting of the CNS that has potential for outpatient use in both children and adults. We believe the NHP biodistribution data, together with our additional preclinical data, reaffirm our clinical development strategy utilizing IT administration and provide translational support for the broad clinical effect reported following treatment with TSHA-102 in both our REVEAL adolescent/adult trial and REVEAL pediatric trial."

08:09 EDT Walmart launches same-day pharmacy delivery - Walmart announced that it is expanding delivery offerings - integrating prescription medications and general merchandise into one streamlined single order for delivery. The new offering is now live in six states: Arkansas, Missouri, New York, Nevada, South Carolina and Wisconsin. By the end of January 2025, Walmart's Pharmacy Delivery is expected to be available in 49 states, reaching tens of millions of customers. Pharmacy Delivery is available for both new prescriptions along with medication refills.

08:08 EDT Akebia signs commercial supply contract with dialysis organization - Akebia Therapeutics announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo for patients on dialysis. The contract enables physicians to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia expects Vafseo will be available in the U.S. in January 2025.

08:08 EDT Allarity granted EPO for DRP companion diagnostic for stenoparib - Allarity Therapeutics announced that the European Patent Office, EPO, has issued a formal notice of its intention to grant a patent for Allarity's Drug Response Predictor, DRP, companion diagnostic specific to stenoparib, the Company's dual-targeted PARP/Tankyrase inhibitor. This patent represents a significant step forward in securing Allarity's market position for stenoparib and the Stenoparib DRP companion diagnostic, which identifies patients most likely to derive clinical benefit from stenoparib treatment.

08:08 EDT Flag Ship Acquisition enters into merger agreement with Great Rich Technologies - Flag Ship Acquisition has signed a definitive merger agreement with Great Rich Technologies and GRT Merger Star - Merger Sub. Upon completion of the merger, shareholders of Flag Ship will receive ADSs of GRT and Flag Ship will be merged into the Merger Sub, a wholly-owned subsidiary of GRT. Completion of the merger will be subject to customary closing conditions. GRT, a Hong Kong entity, has been in the business of developing and mass producing various optoelectronic products for more than a decade. It is publicly listed in South Korea, and has been pursuing expansion with new factories and production line projects in China in recent years. Each ordinary share of Flag Ship will be automatically cancelled, extinguished and exchanged for the right to receive, immediately upon consummation the merger, one ordinary share of GRT payable in ADSs of GRT. The closing conditions of the merger include, among others, the approval of the merger by Flag Ship's existing shareholders and approvals from GRT shareholders, and the approval for listing of GRT's ADSs on the Nasdaq Stock Market.

08:07 EDT Nukkleus announces 1-for-8 reverse stock split - Nukkleus announced that it will effect a 1-for-8 reverse split of the issued shares of its common stock, effective on October 24, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, October 24, 2024. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Global Market under the symbol "NUKK."

08:06 EDT Monopar Therapeutics presents data from radiopharma program based on MNPR-101 - Monopar Therapeutics is presenting data from the clinical and preclinical development of its novel radiopharma program based on MNPR-101 at the European Association of Nuclear Medicine, EANM, 2024 Annual Congress held in Hamburg, Germany. MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. "We were able to optimize our uPAR-targeted radiopharmaceuticals in preclinical studies, and the data show these efforts have translated directly into humans with encouraging tumor uptake. Even at the highest Lu-177 therapeutic antibody dose we are aware of in the clinic, we estimate a favorable radiation dosimetry safety profile for off-target effects such as bone marrow exposure," said Andrew Cittadine, Monopar's Chief Operating Officer.

08:04 EDT Onfolio aquires Eastern Standard Business - Onfolio announced that it has successfully completed the previously disclosed transaction to acquire the majority interest in the assets of Eastern Standard. Eastern Standard provides clients with digital marketing services including integrated branding, and digital customer experiences. "We continue to maintain an active pipeline of profitable companies we can acquire and expect that our Special Purpose Vehicle model, along with our non-convertible Series A Preferred Shares, will continue to play an important part of our future acquisitions," commented Onfolio CEO Dominic Wells.

08:03 EDT ZyVersa Therapeutics announces publication of data on obesity, neuroinflammation - ZyVersa Therapeutics highlights data published in the peer-reviewed journal, Aging Cell, demonstrating that obesity in older adults or prolonged duration of obesity in the younger population resulted in inflammation and suppression of neurotrophic/neuroprotective factors in the brain, indicating that age and duration of obesity are critical risk factors for neurodegenerative diseases. The paper titled, Age and duration of obesity modulate the inflammatory response and expression of neuroprotective factors in mammalian female brain, summarizes research conducted in a diet-induced obesity mouse model. To characterize the effects of age and duration of obesity, adolescent and mature adult female mice were fed a high fat diet for either 13 or 26 weeks. Age-matched control mice were fed a standard diet. Key findings: HFD induced a typical obesity phenotype in mice independent of age and duration; Significant weight gain, increase in fat cell size, and subcutaneous adipose tissue inflammation; At 13 weeks, adolescent obese mice developed a limited inflammatory response in the hypothalamus, but when the duration was extended to 26 weeks: A systemic inflammatory response was demonstrated; Inflammation was demonstrated in visceral adipose tissue, which is responsible for comorbidities, and in all three brain regions studied; Neurotrophic/neuroprotective factors were suppressed; Microgliosis and astrogliosis developed, which are associated with brain damage; Unlike adolescent mice at 13 weeks, mature adult mice demonstrated systemic inflammation and suppression of neurotrophic/neuroprotective factors in all three brain regions studied. This was sustained through the 26-week study, suggesting that advanced age may negatively affect obesity outcomes earlier than in younger individuals.

07:54 EDT BriaCell announces survival data from Phase 2 metastatic breast cancer study - BriaCell Therapeutics announces new survival data, outperforming patients, and survival rates in its Phase 2 metastatic breast cancer study. In BriaCell's Phase 2 clinical study, patients treated with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55%. This rate exceeds the survival data of the current standard of care for similar patients. Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well, including: Patient 01-009: Overall survival of 25 months has been reported in a patient who had failed 6 prior treatments prior to the BriaCell regimen. Stable disease and lymph node shrinkage has been recorded during 13 cycles of therapy. Patient 07-001: OS of 24 months. She had stable disease and received 8 cycles of BriaCell's therapy. Patient 16-003: OS of 15 months and received 8 cycles of therapy with stable disease. Prior to the BriaCell regimen, she had 7 lines of therapy, which included the progression of disease while on the antibody-drug conjugate Enhertu. Patient 11-018: OS of 14 months. This previously-reported responder with 100% resolution of her brain metastasis has recently completed her 19th cycle of therapy. The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 were treated with the formulation currently being used in BriaCell's ongoing pivotal Phase 3 study in metastatic breast cancer. Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive. No Bria-IMT related discontinuations have been reported to date.

07:46 EDT Jacobs selected by US Bureau of Reclamation for New Mexico water project - Jacobs was selected by the U.S. Bureau of Reclamation to design and build the San Juan Lateral Water Treatment Plant in northwest New Mexico. At a cost of $267M, the plant is the largest and most important component of the Navajo-Gallup Water Supply Project. When completed, the project will provide water supplies to approximately 250,000 people in 43 Navajo chapters. Jacobs will design and build the San Juan Lateral Water Treatment Plant to initially treat up to 18.8 million gallons of water per day, with the ability to double the plant's capacity. At full build-out the plant will be able to serve over 200,000 people. The project is 70% complete, with initial water deliveries expected in late 2028 and final completion by the end of 2029.

07:39 EDT GE Aerospace CEO says taking steps with suppliers to increase inputs - Also says making progress on Leap durability.

07:38 EDT Siga Technologies enters exclusive license agreement with Vanderbilt University - SIGA Technologies entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exercised its option to license the exclusive rights to develop, manufacture, and commercialize these mAbs globally. Developed by James Crowe, Jr., M.D., Professor of Pediatrics, Pathology, Microbiology and Immunology at Vanderbilt University Medical Center, these mABs have demonstrated promise in preclinical models and could potentially be used as standalone treatments or in combination with TPOXX. The U.S. Department of Defense is currently funding the development of these mAbs as potential orthopoxvirus treatments through Phase 1 clinical trials under a contract awarded to a contract manufacturing organization with biologics expertise. The financial terms of the transaction were not disclosed.

07:36 EDT Lockheed Martin reports Q3 cash from operations of $2.4B; free cash flow $2.1B

07:36 EDT U.S. Army awards Teledyne $91M contract for Black Hornet 4 drone systems - Teledyne FLIR Defense, part of Teledyne Technologies Incorporated has won a five-year contract worth up to $91M to provide its Black Hornet 4 Personal Reconnaissance Systems to the United States Army. The advanced nano-unmanned aerial systems UAS are being acquired under the Soldier Borne Sensor SBS program, Phase II...Teledyne FLIR has received $25M in initial orders that will cover delivery of the first tranche of Black Hornet 4 drones, as well as controllers, spare parts, and training.The U.S. Army began acquiring Black Hornet 3 systems for the original SBS program in 2018. Since then, they have placed orders totaling more than $215M for the multi-faceted drone. Soldiers are using the UAVs to augment squad and small unit surveillance and reconnaissance capabilities.

07:34 EDT Lockheed Martin sees FY24 cash from operations ~$7.95B vs. prior $7.75B-$8.05B - Backs FY24 CapEx view ~$1.75B.

07:33 EDT Lexeo Therapeutics to present interim data from Phase 1/2 trial of LX1001 - Lexeo Therapeutics announced that interim data from the ongoing Phase 1/2 trial of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer's disease. The Phase 1/2 clinical trial is an open-label, dose-ranging study evaluating the safety and tolerability of LX1001 in fifteen patients with Alzheimer's disease and two copies of the APOE4 allele. Study enrollment was completed in Q4 2023. The presentation will review safety as well as multiple measures of efficacy, including protein expression and tau and amyloid biomarkers. 12-month data will be presented for all patients in Cohorts 1-3, and 6-month data for Cohort 4.

07:32 EDT Lockheed Martin sees FY24 free cash flow ~$6.2B vs. prior view $6B-$6.3B

07:28 EDT Immunic announces outcome of ENSURE program - Immunic announced the outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, nuclear receptor related 1, or Nurr1, activator, vidofludimus calcium, or IMU-838, for the treatment of relapsing multiple sclerosis, or RMS. Based on the outcome of the interim futility analysis, an unblinded Independent Data Monitoring Committee, or IDMC, has recommended that the trials are not futile and should continue as planned. The interim futility analysis of the phase 3 ENSURE program was performed by an unblinded IDMC and based on a pre-specified assessment after approximately half of the planned first relapse events occurred in the double-blind treatment periods of each of the twin ENSURE-1 and ENSURE-2 trials. The analysis was intended to inform potential sample size adjustment and help prevent the final study readout from occurring before sufficient events have been achieved. The unblinded IDMC was asked to make two decisions: The first question, as to whether the trials are futile, was answered by the IDMC with "futility criteria have not been met." The second question, as to whether the sample size in each trial should be increased, was answered by the IDMC with "continue as planned." Both decisions were based on the conditional power of the trials at the time of the interim analysis. Immunic has remained blinded during the interim analysis and has not seen any of the data available to the IDMC to make their recommendations. The ongoing ENSURE program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in RMS patients. Each of the trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than 100 sites in more than 15 countries, including the United States, India and countries in Latin America, Central and Eastern Europe. Patients are being randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo and the primary endpoint for both trials is time to first relapse up to 72 weeks. Key secondary endpoints include time to confirmed disability worsening based on Expanded Disability Status Scale disability progression, volume of new T2-lesions, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change, grey matter volume and white matter volume. As previously reported, completion of ENSURE-1 is anticipated in the second quarter of 2026, with completion of ENSURE-2 expected in the second half of 2026.

07:23 EDT Compass Digital Acquisition, EEW Renewables release investor webcast - EEW Renewables and Compass Digital Acquisition announced the release of an investor webcast related to the proposed business combination agreement (providing for the proposed business combination between CDAQ and EEW. The investor webcast includes a presentation from the EEW and CDAQ leadership teams. The presentation provides the latest views on EEW's renewable energy thesis, business model, addressable market opportunity, market growth drivers, project pipeline, financial outlook, and transaction overview. On September 6, 2024, EEW and CDAQ announced that they entered into a definitive business combination agreement subject to customary closing conditions, including regulatory and CDAQ stockholder approvals. The combined public company is expected to list its common stock and warrants to purchase common stock on Nasdaq, subject to approval of its listing application. The Proposed Business Combination has been unanimously approved by the Board of Directors of both EEW and CDAQ.

07:19 EDT TreeHouse expands voluntary recall to all products made at one facility - TreeHouse Foods is expanding its voluntary recall to include all products manufactured at one facility and still within their shelf-life. The recall is expanded to include frozen toaster waffle, Belgian waffle and pancake products, due to the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes is an organism that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain, and diarrhea. Listeria monocytogenes infection can cause miscarriages and stillbirths among pregnant women. Recalled products were distributed throughout all states and provinces within the United States and Canada and packed in various formats under the brand names listed below. Consumers and retailers can identify the UPC on the back of the carton, and the Lot Code and Best By Date for these products on the end of the carton. Photos of the affected products can also be found on this site. The following products, which are sold through most retail stores, including but not limited to Albertson's, Aldi, Dollar General, Foodhold, HEB, Kroger, Publix, Target and Walmart, are included in this recall with Best By or Best if Used by Dates as indicated in the below table. All Lot Codes in scope of this recall will begin with 2C.

07:17 EDT Garmin acquires 'a leader in marine LED lighting' Lumishore, no terms - Garmin announced it has acquired Lumishore, a privately-held company that designs and manufactures high-performance above and underwater LED lighting systems for boats."Lumishore brings an exciting new product category that complements Garmin's existing marine portfolio and furthers our ability to provide seamless vessel integration. As a technology leader in LED lighting, Lumishore will expand Garmin's innovative solutions all around the vessel. Together, we look forward to delivering unmatched LED lighting technology to our customers around the world." Jarrod Seymour, Garmin Vice President, Marine Segment...Lumishore is headquartered in Swansea, United Kingdom with a distribution center in Sarasota, Fla. A vertically integrated company with in-house R&D and production, its associates will become part of the global Garmin workforce. Financial terms of the acquisition will not be disclosed..

07:16 EDT Xtract One secures contract with glonal automotive manufacturer - Xtract One Technologies announced that its AI-based security solutions have been chosen by a leading global automotive manufacturer of cars, SUVs, and pickup trucks to secure five of its North American facilities. System deployment will start at their Tennessee and Ohio locations, with plans for future installation at more facilities. After a comprehensive evaluation of available solutions, Xtract One was selected for the Company's precise weapons detection capabilities and flexible integration into daily business operations and the physical environment.

07:15 EDT Clearside Biomedical announces multiple presentations delivered at 2024 AAO - Clearside Biomedical announced that multiple presentations were delivered at the 2024 Annual Meeting of the American Academy of Ophthalmology, AAO, and preceding events that highlighted encouraging safety and efficacy data from clinical trials of therapies utilizing Clearside's SCS Microinjector(R) to deliver drugs into the suprachoroidal space to treat a variety of retinal diseases.

07:11 EDT Denny's sees FY24 adjusted EBITDA $81M-$84M - The following full year 2024 expectations reflect management's expectations that the current consumer and economic environment will not change materially, as well as the Company's strategic initiative to accelerate the closure of lower volume Denny's restaurants. Denny's domestic system-wide same-restaurant sales between (1%) and 0%. Consolidated restaurant openings of 30 to 40, including 12 to 16 new Keke's restaurants, with a consolidated net decline of 45 to 55. Commodity inflation of approximately 2%. Labor inflation between 3% and 4%. Total general and administrative expenses between $82 million and $85 million, including approximately $11 million related to share-based compensation expense which does not impact Adjusted EBITDA. Adjusted EBITDA between $81 million and $84 million .

07:10 EDT Laser Photonics 'lands sale' of CTIR-3050 to Thermodyne Powder Coating - Laser Photonics announced the sale of its CleanTech Industrial Roughening Laser 3050 to Thermodyne Powder Coating, a top provider of powder coating services in Florida that serves hotels, resorts, marinas, boatyards, homeowner associations, condominium complexes and the auto restoration industry. LPC is to deliver its CleanTech Industrial Roughening Laser 3050 to Thermodyne Power Coating in a sale that marks the beginning of the two companies' relationship. Thermodyne specializes in applying a custom-formulated powder coating that is baked to create a durable, protective and attractive finish. These powders, made from resin mixed with pigments, are melted at precise temperatures and cured into a tough, versatile coating. While not indestructible, powder coat finishes are stronger, thicker, and offer better coverage than most standard paints. The CTIR-3050 will be used at Thermodyne's facility to streamline and enhance pretreatment processes. Thermodyne works with companies in a number of industries, especially those in the maritime sector. Coastal regions like Florida present harsh conditions for marine craft and structures due to saltwater, sun and air. Thermodyne's marine-grade powder coating protects parts, boats, docks and structures from corrosion while preserving their appearance. "

07:07 EDT CytoSorbents announces FDA has accepted De Novo medical device application - CytoSorbents (CTSO) announced the U.S. Food and Drug Administration, FDA, has accepted its De Novo medical device application for DrugSorb-ATR and initiated substantive review. The goal of DrugSorb-ATR, an investigational medical device, is to reduce the severity of perioperative bleeding in patients on ticagrelor, Brilinta, AstraZeneca (AZN), undergoing coronary artery bypass graft, CABG, surgery. The FDA De Novo pathway provides a regulatory process for novel medical devices that are found to be low to moderate risk and lack an appropriate predicate device. Acceptance of the company's De Novo application follows FDA's previous granting of Breakthrough Device Designation to DrugSorb-ATR, making it eligible for priority review. The Company anticipates an FDA decision in 2025.

07:07 EDT TD Bank joins LTX as a liquidity provider - LTX, an AI-powered corporate bond trading platform backed by Broadridge Financial (BR), announced that TD Bank (TD) has joined its e-trading platform through its subsidiary TD Securities Automated Trading LLC. TD Bank will contribute axes, or pre-trade indications of interest, to LTX's Liquidity Cloud and utilize LTX's RFQ+ protocol to provide Investment Grade and High Yield bond liquidity to its institutional clients.

07:06 EDT Verizon reports Q3 wireless retail postpaid phone net additions of 239,000 - Total wireless service revenue of $19.8 billion, a 2.7 percent increase year over year. Retail postpaid phone net additions of 239,000, and retail postpaid net additions of 349,000. Retail postpaid phone churn of 0.89 percent, and retail postpaid churn of 1.16 percent.

07:05 EDT RedHill Biopharma signs research pact with Duke University School of Medicine - RedHill Biopharma announced the signing of a collaborative research agreement with Duke University School of Medicine outlining plans for multiple in vivo studies. The program is designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury, aimed at providing results sufficient to advance opaganib into further definitive U.S. government-sponsored development under the U.S. FDA Animal Rule pathway to approval. The FDA Animal Rule allows for the use of pivotal animal model efficacy studies to support FDA approval of new drugs when human clinical trials are not ethical or feasible. Under this research agreement, RedHill will provide required drug quantities for animal studies, analytical support to quantify drug concentrations in plasma samples, and share dosing regimen with the Achanta Lab at Duke University.

07:02 EDT BGC Group to acquire OTC Global Holdings in an all-cash transaction - BGC Group announced that it has entered into an agreement to acquire OTC Global Holdings, the largest independent institutional energy and commodities brokerage firm. Through this acquisition, BGC Group will further expand and diversify its global Energy, Commodities, and Shipping business. Under the terms of the agreement, BGC expects to acquire OTC in a substantially all-cash transaction, which is subject to customary closing conditions, including applicable regulatory approvals.

06:38 EDT GE Aerospace positioned to deliver 'solid' year, says CEO Culp - GE Aerospace Chairman and CEO H. Lawrence Culp, Jr. said, "The GE Aerospace team delivered strong results, with demand driving orders up 28%. We grew earnings 25% and produced substantial free cash flow, both largely driven by services. Given the strength of our results and 4Q expectations, we're raising our earnings and cash guidance for the year." Culp continued, "Leveraging FLIGHT DECK we're focused on servicing and delivering our engines faster without compromising safety and quality. While there's more work to do, we made meaningful progress with engine deliveries improving more than 20% sequentially while also expanding aftermarket capacity. Our path forward is clear, and I am confident GE Aerospace is positioned to deliver a solid year in our first year as a standalone company."

06:32 EDT PulteGroup reports home sale gross margin of 28.8%

06:31 EDT Modine Manufacturing selected as thermal solutions supplier for Gillig - Modine announced it is the thermal management supplier for Gillig, a manufacturer of heavy-duty transit buses in the United States, for their hybrid vehicles, powered by the Allison eGen Flex system. Through this collaboration, Modine provides its advanced EVantage Battery Thermal Management Systems, or BTMS, and inverter cooling module for the Gillig Hybrid bus.

06:07 EDT BitFuFu to acquire 80-MW Bitcoin mining facility in Ethiopia - BitFuFu announced it has entered into a definitive agreement to acquire a majority stake in an 80-megawatt Bitcoin mining facility in Ethiopia. This transaction marks the start of the company's transition from an asset-light strategy to one that manages a diverse and robust portfolio of Bitcoin mining infrastructure. As of June 30, 2024, BitFuFu's hosting capacity was 522 MW, all of which is hosted by third parties. Upon completion of this transaction, BitFuFu's hosting capacity will surpass the 600MW mark, approximately 13% of which will reside in sites owned and operated by the company. The newly acquired mining facility will provide BitFuFu with the potential to add 4.6 EH/s mining capacity with the deployment of the latest Bitmain S21-series miners. With power costs averaging below $0.04 per kilowatt-hour, this acquisition is expected to reduce BitFuFu's cost per Bitcoin. With the majority of BitFuFu's mining infrastructure currently based in the United States, this acquisition strengthens the company's competitive advantages in the international market and further expands its footprint globally. Additionally, the new facility will create valuable employment opportunities for the local community, contributing to regional economic development.

06:02 EDT Estee Lauder announces U.S. Amazon Premium Beauty Store debut - Estee Lauder, the flagship brand of The Estee Lauder Companies (EL), announces its official launch in the U.S. Amazon (AMZN) Premium Beauty store, bringing its high-performance skincare and makeup and legendary fragrances to Amazon shoppers across the country. Amazon customers can start shopping now at amazon.com/esteelauder. The brand is also debuting a Virtual Foundation Tool, exclusive to Amazon, at amazon.com/findyourdoublewear. This tool allows Amazon customers to compare multiple shades of Estee Lauder foundation virtually, find their shade, and add it right to their Amazon shopping cart. When shopping Estee Lauder in the Amazon Premium Beauty store, Prime members enjoy fast, free shipping on every order

05:56 EDT Meta testing facial recognition for spotting 'celeb-bait' ads scams - Meta said in a blog post on Monday: "Scammers are relentless and continuously evolve their tactics to try to evade detection, so we're building on our existing defenses by testing new ways to protect people and make it harder for scammers to deceive others. We're testing the use of facial recognition technology to detect and prevent celeb-bait ads on our platforms. We're also testing this technology as a means for people to verify their identity and regain access to compromised accounts." The company said "Scammers often try to use images of public figures, such as content creators or celebrities, to bait people into engaging with ads that lead to scam websites, where they are asked to share personal information or send money. This scheme, commonly called 'celeb-bait,' violates our policies and is bad for people that use our products." Meta said early testing with a small group of celebrities and public figures "shows promising results in increasing the speed and efficacy with which we can detect and enforce against this type of scam." In the coming weeks, Meta said it will start showing in-app notifications to a larger group of public figures who've been impacted by celeb-bait "letting them know we're enrolling them in this protection." Reference Link

05:14 EDT Molecular Partners expands 212Pb co-development agreement with Orano Med - Molecular Partners announced the strengthening of a previously announced co-development agreement with Orano Med, a clinical-stage radiopharmaceutical company developing targeted alpha therapies with lead-212, or 212Pb, where both companies will develop and market 212Pb-based Radio-DARPin Therapeutics for the treatment of cancer. This revision builds on the original agreement signed in January, under which both companies agreed to co-develop Radio-DARPin Therapeutics. For the first program, MP0712, a DLL3-targeting Radio-DARPin, Molecular Partners holds the commercialization rights. The amended agreement now targets four programs, with each company holding the commercialization rights to two of these programs. Both companies anticipate initiating first-in-human studies for MP0712, pending regulatory clearance, in 2025. Molecular Partners will hold the second program's commercialization rights, and Orano Med will have the rights to develop and commercialize programs three and four. Molecular Partners expects no immediate impact on its financial forecast for the fiscal year 2024 from the expansion of the co-development agreement and maintains its funding guidance into 2027. Cash and cash equivalents as of September 30 are currently estimated at approximately CHF 140M.

05:06 EDT DDC Enterprise issues letter to shareholders - DDC Enterprise issued a corporate update in a letter to shareholders from CEO Norma Chu: "I am pleased to share important updates and improvements from DayDayCook as we reflect on our first year as a publicly listed company. While we have faced our share of challenges during this transition, we have proactively addressed them and are emerging as a stronger organization. To enhance our operational capabilities, we have established a new finance and accounting team dedicated to managing our ongoing financial filing requirements. On September 30, 2024 we appointed Enrome LLP ("Enrome") as our independent registered public accounting firm. This engagement will be led by our newly hired co-CFO and principal accounting officer, Tony Tao. Additionally, we welcomed Jeff Ervin in June, who serves as co-CFO in a fractional capacity, focusing on our strategic financial initiatives. With this experienced finance team in place, we are confident in our ability to meet future filing deadlines. The Company ended 2023 with estimated total 2023 revenue between $28 and $29 million USD, representing an increase of 10-14% over 2022. Profitability also improved with gross margin increasing from 24.5% to an estimated 24.9-25.1% by the end of the year. We ended 2023 with estimated USD 25.8m of cash and short-term investment. This year, we successfully completed two important acquisitions that enhance our presence in the United States: Yai's Thai and Omsom. These well-respected brands align perfectly with our business vision. Following the acquisition of Yai's Thai, we implemented distribution synergies that expanded brand availability with retailer Sprouts, resulting in a nationwide launch of Yai's Thai packaged sauce series and a notable increase in presence across Sprouts locations. We remain disciplined in our analysis of acquisition opportunities, focusing on targets that not only broaden our product portfolio but also deliver meaningful financial and operational synergies. In June, we welcomed Malik Sadiq as Chief Operating Officer, who brings invaluable industry experience and expertise in integrating acquisitions and optimizing internal efficiencies. In August, we announced the successful elimination of $4.8 million in debt, significantly enhancing our balance sheet. We anticipate utilizing cash on hand and other strategic measures to further reduce outstanding debt by year-end. We believe that the current interest rate environment and our balance sheet improvements will enable us to refinance additional outstanding obligations, resulting in increased future cash flows. Overall, we have enriched our leadership team with experienced professionals who are committed to refining our internal processes. With our portfolio of well-recognized Asian food brands, including Omsom, Yai's Thai, and others, we have a robust foundation for sustainable growth. We believe that DayDayCook is well positioned to become the most influential player in the Asian food market in the U.S. Additionally, with our foundational operations in China, we expect to benefit from the recent announcement of economic stimulus in the country. Together, these factors position us to seize the momentum in the ready-to-heat and ready-to-eat Asian food market."